Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Next Previous
Trial Profile

An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Perampanel (Primary)
  • Indications Partial epilepsies
  • Focus Adverse reactions; Registrational
  • Sponsors Eisai Co Ltd; Eisai Inc

Most Recent Events

  • 06 Dec 2022 Results from NCT00735397 and NCT01618695; assessing the long-term efficacy and safety of perampanel, patients with FOS, with or without FBTCS presented at the 76th Annual Meeting of the American Epilepsy Society
  • 01 Oct 2022 Results of post-hoc analysis of open-label extension studies (Study 307, Study 235, Study 332 and Study 335) assessing long-term efficacy and safety of adjunctive perampanel in adolescent patients with focal-onset seizures (FOS), with/without focal to bilateral tonic-clonic seizures (FBTCS), or generalized tonic-clonic seizures, published in the Epilepsy and Behavior.
  • 26 Apr 2022 Results of pooled analysis from Studies 307, 335, 412, 342, and 506 assessing perampanel in elderly patients presented at the 74th Annual Meeting of the American Academy of Neurology 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top